FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology; it can be used to predict the degree of risk of developing hematogenous metastases in invasive carcinoma of a non-specific type of mammary gland based on the assessment of the expression of LIMCH1 protein. A study of patient’s tumor tissue and the subsequent calculation of a diagnostic indicator are carried out. Using immunohistochemical studies, a value of the cytoplasmic expression of LIMCH1 protein in tumor cells is determined and evaluated in points. If the number of cells with cytoplasmic expression of LIMCH1 protein is more than or equal to 1, the value is estimated at 2 points. If the number of cells with cytoplasmic expression of LIMCH1 protein is less than 1, the value is estimated at 1 point. A value of a regression equation Y is calculated using the formula Y=-4.39+3.04·X1, where -4.39 is a value of a regression coefficient of a free term; X1 is the value of the cytoplasmic expression of LIMCH1 protein in tumor cells of invasive carcinoma of mammary gland in points; 3.04 is the value of the regression coefficient of this trait. Next, a value of the probability of developing hematogenous metastases P is determined using the formula P=eY/(1+eY), where e is mathematical constant equal to 2.72. If P is more than or equal to 50%, a high risk is determined, and if P is less than 50%, a low risk of developing hematogenous metastases is determined.
EFFECT: method makes it possible to predict the level of risk of developing hematogenous metastases in invasive carcinoma of a non-specific type of mammary gland by determining the cytoplasmic expression of LIMCH1 protein in tumor cells and using a mathematical model to calculate the probability of developing hematogenous metastases, which makes it possible to simplify and increase the accuracy and informativeness of the method.
1 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREDICTING HEMATOGENOUS METASTASIS IN INVASIVE CARCINOMA OF NONSPECIFIC TYPE OF MAMMARY GLAND BASED ON DETERMINATION OF DIFFERENT POPULATIONS OF CIRCULATING TUMOR CELLS IN BLOOD BEFORE TREATMENT | 2018 |
|
RU2678202C1 |
METHOD FOR PREDICTING LYMPHOGENOUS METASTASIS IN INVASIVE CARCINOMA OF NONSPECIFIC TYPE OF MAMMARY GLAND | 2016 |
|
RU2659938C2 |
METHOD FOR PREDICTION OF LYMPHATIC CANCER SPREAD ACCOMPANYING NON-SPECIFIC BREAST CARCINOMA | 2014 |
|
RU2566732C1 |
METHOD FOR PREDICTION OF HAEMATOGENIC METASTASIS IN DOUBLE-SIDED SYNCHRONOUS INVASIVE NON-SPECIFIC BREAST CARCINOMA | 2015 |
|
RU2589287C1 |
METHOD FOR PREDICTING RISK OF LYMPHATIC CANCER SPREAD IN BREAST CANCER BASED ON YKL-39 PROTEIN GENE EXPRESSION | 2016 |
|
RU2632115C1 |
METHOD FOR PREDICTION OF HAEMATOGENOUS METASTASIS IN TRIPLE NEGATIVE INVASIVE NON-SPECIFIC BREAST CARCINOMA | 2014 |
|
RU2558863C1 |
METHOD FOR HEMATOGENIC METASTASING PREDICTION IN CASE OF NON-SPECIFIC INVASIVE CARCINOMA OF BREAST IN PATIENTS WITH GOOD RESPONSE TO NEOADJUVANT CHEMOTHERAPY | 2016 |
|
RU2627649C1 |
METHOD FOR PREDICTION OF HAEMATOGENIC METASTASIS IN DOUBLE-SIDED METACHROMIC INVASIVE NON-SPECIFIC BREAST CARCINOMA | 2015 |
|
RU2580639C1 |
METHOD OF FORECASTING PERSONSIVE SURVIVABILITY IN PATIENTS WITH BREAST CANCER | 2016 |
|
RU2623869C1 |
METHOD FOR PREDICTION OF LYMPHATIC CANCER SPREAD ACCOMPANIED BY INVASIVE NONSPECIFIC TRIPLE-NEGATIVE BREAST CANCER | 2014 |
|
RU2558860C1 |
Authors
Dates
2021-09-14—Published
2020-03-25—Filed